Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

<table class="table-group" id="tab5"><tr><td><table class="table"><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr class="thead"><td class="align_left"> </td><td class="align_center">Ineffective</td><td class="align_center">Mild efficacy</td><td class="align_center">Significant efficacy</td><td class="align_center">Total</td></tr><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr><td class="align_left">Group 1</td><td class="align_center">22 (44.0%)</td><td class="align_center">20 (40.0%)</td><td class="align_center">8 (16.0%)</td><td class="align_center">50 (100%)</td></tr><tr><td class="align_left">Group 2</td><td class="align_center">27 (54.0%)</td><td class="align_center">16 (32.0%)</td><td class="align_center">7 (14.0%)</td><td class="align_center">50 (100%)</td></tr><tr><td class="align_left">Group 3</td><td class="align_center">6 (13.0%)</td><td class="align_center">28 (60.9%)</td><td class="align_center">12 (26.1%)</td><td class="align_center">46 (100%)</td></tr><tr class="table-tr"><td colspan="5"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Therapeutic effectiveness in the three groups.

Gastroenterology Research and Practice

tab5

Table 5

Table 5: Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus 

Table 5 | Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus 